For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Sarepta Therapeutics Inc’s stock clocked out at $21.14, down -5.24% from its previous closing price of $22.31. In other words, the price has decreased by -$5.24 from its previous closing price. On the day, 2.54 million shares were traded. SRPT stock price reached its highest trading level at $22.4 during the session, while it also had its lowest trading level at $21.055.
Ratios:
To gain a deeper understanding of SRPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 2.95. In the meantime, Its Debt-to-Equity ratio is 0.95 whereas as Long-Term Debt/Eq ratio is at 0.95.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on December 09, 2025, initiated with a Outperform rating and assigned the stock a target price of $32.
On November 05, 2025, Mizuho Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $26.
BMO Capital Markets Upgraded its Market Perform to Outperform on September 22, 2025, while the target price for the stock was maintained at $50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 16 ’25 when IAN M ESTEPAN bought 13,187 shares for $22.31 per share.
Sarepta Therapeutics, Inc. bought 9,265,312 shares of SRPT for $185,213,587 on Aug 13 ’25. On Mar 12 ’25, another insider, Nicaise Claude, who serves as the Director of the company, sold 2,491 shares for $99.64 each. As a result, the insider received 248,203 and left with 27,812 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 2215201024 and an Enterprise Value of 2624564224. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.92 while its Price-to-Book (P/B) ratio in mrq is 1.68. Its current Enterprise Value per Revenue stands at 1.087 whereas that against EBITDA is -72.334.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.47, which has changed by -0.8132585 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $129.84, while it has fallen to a 52-week low of $10.41. The 50-Day Moving Average of the stock is 1.22%, while the 200-Day Moving Average is calculated to be -35.79%.
Shares Statistics:
It appears that SRPT traded 5.28M shares on average per day over the past three months and 3232400 shares per day over the past ten days. A total of 104.77M shares are outstanding, with a floating share count of 98.62M. Insiders hold about 5.88% of the company’s shares, while institutions hold 85.71% stake in the company. Shares short for SRPT as of 1764288000 were 19565034 with a Short Ratio of 3.71, compared to 1761868800 on 17313065. Therefore, it implies a Short% of Shares Outstanding of 19565034 and a Short% of Float of 21.65.
Earnings Estimates
Sarepta Therapeutics Inc (SRPT) is currently under the scrutiny of 12.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.73, with high estimates of $1.43 and low estimates of $0.42.
Analysts are recommending an EPS of between $2.3 and -$4.31 for the fiscal current year, implying an average EPS of -$2.01. EPS for the following year is $2.9, with 13.0 analysts recommending between $6.09 and -$2.73.
Revenue Estimates
In. The current quarter, 20 analysts expect revenue to total $379.47M. It ranges from a high estimate of $531.64M to a low estimate of $336.25M. As of. The current estimate, Sarepta Therapeutics Inc’s year-ago sales were $658.41MFor the next quarter, 20 analysts are estimating revenue of $375.7M. There is a high estimate of $433.4M for the next quarter, whereas the lowest estimate is $344.04M.
A total of 21 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $2.16B, while the lowest revenue estimate was $2.02B, resulting in an average revenue estimate of $2.12B. In the same quarter a year ago, actual revenue was $1.9BBased on 21 analysts’ estimates, the company’s revenue will be $1.59B in the next fiscal year. The high estimate is $2.24B and the low estimate is $1.31B.
